In News, UK News

bionow

 

The UK’s innovation agency, the Technology Strategy Board’s announcement today that the Biomedical Catalyst will reopen for applications for early- and late-stage awards on 29 July 2013 is welcome. The announcement follows a successful campaign and confirmation at the Spending Review of additional funding for the Technology Strategy Board.

The Biomedical Catalyst, launched as part of the government’s Strategy for UK Life Sciences in December 2011, has been a major success. To date the government-backed Technology Strategy Board has funded more than 80 projects accelerating medical research and leveraging more than £55 million in additional private funding.

Steve Bates, BIA Chief Executive Officer, said:
“The BIA welcomes the Technology Strategy Board’s decision to reopen the Biomedical Catalyst at the end of July. I know many companies are waiting for the opportunity to make applications. I encourage companies to prepare their applications as I am certain there will be strong demand once again.”

Geoff Davison, Bionow Chief Executive Officer, said:
“Given the announcement of another round of this critical funding source, Bionow is keen to encourage more applications by companies across the UK. We will be working with partners to ensure that our members have every opportunity to apply for funding via this route.”

Lin Bateson, BioPartner Executive Director, said:
“This announcement reinforces external perception of the UK’s commitment to life science business growth, and will assist many future global collaborations.”

Harriet Fear, One Nucleus Chief Executive, said:
“I’m delighted with the news, announced today by the Technology Strategy Board at the One Nucleus ON Helix Conference in Cambridge. Many of our members have benefitted from previous Biomedical Catalyst rounds and the difference it makes is significant.”

Source: bionow

Contact Us

Send us an email and we'll get back to you asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search